XHKG8189
Market cap67mUSD
Dec 23, Last price
0.28HKD
1D
1.85%
1Q
52.78%
Jan 2017
-62.84%
Name
Tianjin TEDA Biomedical Engineering Co Ltd
Chart & Performance
Profile
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. The company operates in two segments, Biological Compound Fertilizers Products, and Elderly Care and Health Care Services. Its biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formula that are used for the facilitation of balanced growth of grains, fruits, and vegetables. The company is also involved in the provision of integrated elderly and health care; and elderly equipment leasing services, as well as consulting, advisory, and assessment services. In addition, it provides and licenses electroencephalography photography (EEG) diagnosis detection services; and conducts EEG detection and diagnosis technology services. Further, the company engages in the research, development, manufacture, and application of biomedical science and technology projects; regional soil resources conditioning and remediation business; and provision of soil environmental quality standards research services. Tianjin TEDA Biomedical Engineering Company Limited was incorporated in 2000 and is headquartered in Tianjin, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 397,998 -11.49% | 449,676 -5.61% | 476,385 28.98% | |||||||
Cost of revenue | 407,857 | 471,906 | 483,035 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (9,859) | (22,230) | (6,650) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (1,044) | 151 | (55) | |||||||
Tax Rate | ||||||||||
NOPAT | (8,815) | (22,381) | (6,595) | |||||||
Net income | (20,160) -24.34% | (26,646) -40.50% | (44,784) -11.08% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 63,262 | 60,779 | 45,131 | |||||||
Long-term debt | 32,169 | 74,446 | 88,155 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (2,564) | |||||||||
Net debt | 89,497 | 125,676 | 103,507 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (13,155) | (12,821) | (6,684) | |||||||
CAPEX | (2,468) | (8,798) | (33,697) | |||||||
Cash from investing activities | (467) | (12,931) | (8,511) | |||||||
Cash from financing activities | 12,729 | 6,169 | 28,102 | |||||||
FCF | 7,930 | (9,237) | 22,879 | |||||||
Balance | ||||||||||
Cash | 5,934 | 9,549 | 29,779 | |||||||
Long term investments | ||||||||||
Excess cash | 5,960 | |||||||||
Stockholders' equity | (193,897) | (178,481) | (151,835) | |||||||
Invested Capital | 342,034 | 352,515 | 351,053 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 1,894,500 | 1,894,500 | 1,894,500 | |||||||
Price | 0.09 | 0.17 | ||||||||
Market cap | 168,610 | 322,065 | ||||||||
EV | 272,736 | 451,991 | ||||||||
EBITDA | 1,774 | (6,840) | 2,863 | |||||||
EV/EBITDA | 153.71 | 157.86 | ||||||||
Interest | 5,173 | 6,402 | 5,467 | |||||||
Interest/NOPBT |